“This kind of adaptive design has never been used in oncology before. ProBio is the forerunner of actually using this”, says Professor Henrik Grönberg.
Professor Henrik Grönberg, who recently received the award “Cancer Researcher of the Year, 2022” from the Swedish Cancer Society, is the inventor of the Stockholm3 blood test. A simple blood test in which biomarkers are used to detect aggressive prostate cancer at an early stage. A test that replaces traditional PSA screening.
Henrik Grönberg and his colleagues are always eager to do things that no one else has done before. Next up is the ProBio trial, using biomarkers from blood tests to optimize the treatment for prostate cancer, therefore making it possible to provide the correct treatment, at the proper time, to the patient, thus increasing the chances of a longer life.
200 patients are participating in the study. There are 10 centers in Sweden, 10 in Belgium with new centers on the way in Norway and Switzerland. This summer there will be in total 35 centers in different countries, running the ProBiostudy.
Guest: Professor Henrik Grönberg
By: Annette Andrén and Gustav Widar
Contact us: email@example.com
More about personalized therapy?
Previously, in the first episode of Theragnostic Talks, Professor Rodney Hicks talked about the potential for a more personalized therapy, about the importance of giving the correct treatment at the proper time. As did our guest in episode 6, Professor Louise Emmett who talked about how prostate imaging can be used to understand the phenotype of the tumor, a step towards a more personalized treatment.
So – here goes: listen to the earlier episodes here: